Details for Patent: 8,088,368

Title:	Antiviral compounds
Abstract:	The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s):	Guo; Hongyan (Foster City, CA), Kato; Darryl (Foster City, CA), Kirschberg; Thorsten A. (Foster City, CA), Liu; Hongtao (Foster City, CA), Link; John O. (Foster City, CA), Mitchell; Michael L. (Foster City, CA), Parrish; Jay P. (Foster City, CA), Sun; Jianyu (Foster City, CA), Taylor; James (Foster City, CA), Bacon; Elizabeth M. (Foster City, CA), Canales; Eda (Foster City, CA), Cho; Aesop (Foster City, CA), Kim; Choung U. (Foster City, CA), Cottell; Jeromy J. (Foster City, CA), Desai; Manoj C. (Foster City, CA), Halcomb; Randall L. (Foster City, CA), Lazerwith; Scott E. (Foster City, CA), Mackman; Richard L. (Foster City, CA), Pyun; Hyung-Jung (Foster City, CA), Saugier; Joseph H. (Foster City, CA), Trenkle; James D. (Foster City, CA), Tse; Winston C. (Foster City, CA), Watkins; William J. (Foster City, CA), Xu; Lianhong (Foster City, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Filing Date:	May 12, 2010
Application Number:	12/779,023
Claims:	1. A compound of formula: ##STR01319## wherein: V is alkyl; L is benzimidazolyl; M is a 5-membered heteroaryl ring; A.sup.15 is: ##STR01320## P is selected from: ##STR01321## ##STR01322## and R''' is hydrogen or methyl; or a pharmaceutically acceptable salt, or prodrug thereof. 2. The compound of claim 1 that is: ##STR01323## or a pharmaceutically acceptable salt, or prodrug thereof. 3. The compound of claim 1 that is: ##STR01324## or a pharmaceutically acceptable salt, or prodrug thereof. 4. The compound of claim 1 wherein P is selected from: ##STR01325## 5. The compound of claim 1 wherein P is ##STR01326## 6. The compound of claim 1 wherein P is ##STR01327## 7. The compound of claim 1 that is: ##STR01328## or a pharmaceutically acceptable salt, or prodrug thereof. 8. The compound of claim 1 that is: ##STR01329## or a pharmaceutically acceptable salt, or prodrug thereof. 9. A compound: ##STR01330## wherein: V is alkyl; M is a 5-membered heteroaryl ring; and A.sup.15 is: ##STR01331## or a pharmaceutically acceptable salt, or prodrug thereof. 10. A compound: ##STR01332## wherein V is alkyl; and A.sup.15 is: ##STR01333## or a pharmaceutically acceptable salt, or prodrug thereof. 11. The compound of claim 1 wherein each V is: ##STR01334## 12. A compound of formula: ##STR01335## or a pharmaceutically acceptable salt, or prodrug thereof. 13. A pharmaceutical composition comprising the compound as described in claim 1 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier. 14. The pharmaceutical composition of claim 13, further comprising at least one additional therapeutic agent. 15. The pharmaceutical composition of claim 14, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV. 16. The pharmaceutical composition according to claim 13, further comprising a nucleoside analogue. 17. The pharmaceutical composition according to claim 16, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine. 18. A compound of formula: ##STR01336## or a pharmaceutically acceptable salt, or prodrug thereof. 19. A pharmaceutical composition comprising the compound as described in claim 18 or a pharmaceutically acceptable salt, or prodrug thereof and at least one pharmaceutically acceptable carrier. 20. The pharmaceutical composition of claim 19, further comprising at least one additional therapeutic agent. 21. The pharmaceutical composition of claim 20, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV. 22. The pharmaceutical composition according to claim 19, further comprising a nucleoside analogue. 23. The pharmaceutical composition according to claim 22, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.